1. Home
  2. KTB vs ACAD Comparison

KTB vs ACAD Comparison

Compare KTB & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kontoor Brands Inc.

KTB

Kontoor Brands Inc.

N/A

Current Price

$71.74

Market Cap

3.7B

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$21.95

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KTB
ACAD
Founded
2018
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.9B
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
KTB
ACAD
Price
$71.74
$21.95
Analyst Decision
Strong Buy
Buy
Analyst Count
9
22
Target Price
$99.67
$30.45
AVG Volume (30 Days)
898.0K
1.6M
Earning Date
06-03-2026
05-25-2026
Dividend Yield
2.78%
N/A
EPS Growth
N/A
69.12
EPS
4.05
2.30
Revenue
$2,097,839,000.00
$726,437,000.00
Revenue This Year
$10.42
$18.52
Revenue Next Year
$3.62
$11.34
P/E Ratio
$18.81
$9.61
Revenue Growth
N/A
40.45
52 Week Low
$50.00
$14.08
52 Week High
$87.00
$28.35

Technical Indicators

Market Signals
Indicator
KTB
ACAD
Relative Strength Index (RSI) 55.99 37.23
Support Level $68.96 $20.62
Resistance Level $72.31 $22.75
Average True Range (ATR) 3.33 1.05
MACD 0.67 -0.11
Stochastic Oscillator 52.65 8.31

Price Performance

Historical Comparison
KTB
ACAD

About KTB Kontoor Brands Inc.

Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: